Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Aurita
AddedFeb 16, 2024
UpdatedJun 18, 2026
Aurita

Aurita

Pre-Seed

Aurita Bioscience: A synthetic biology startup providing comprehensive 3D bioscience solutions for lab and clinical settings.

HQ
Gainesville, FL, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Aurita Bioscience, founded with the mission to bridge lab and clinical settings through advanced 3D bioscience solutions, aims to revolutionize synthetic biology. The company offers a comprehensive platform that includes 3D culture materials, bioprinting solutions, precision treatment and diagnostics, therapeutic macromolecules, and live cell imaging. Their market focus spans enterprises seeking robust, open 3D culture ecosystems, emphasizing the importance of the microenvironment and its interactions over traditional monolayer approaches.

Notable figures affiliated with Aurita Bioscience include leading scientists and industry experts in synthetic biology and 3D culture technologies. The company has attracted significant investment from venture capital firms specializing in biotech innovations. Key achievements include the development of proprietary products like the Darcy Perfusion Devices and Liquid-Like Solids (LLS™), which have garnered attention for their potential to enhance clinical relevancy in research. Aurita's impact is evident in its contribution to more accurate and effective biomedical research and treatment solutions.

Aurita - Similar Companies

Aureka Biotechnologies logo

Aureka Biotechnologies

aurekabio.com

Aurion Biotech logo

Aurion Biotech

aurionbiotech.com

Arytha Biosciences logo

Arytha Biosciences

arythabio.com

Pearl Bio logo

Pearl Bio

pearlbio.com

Think Bioscience logo

Think Bioscience

Synlife logo

Synlife

synlifebio.com

Arcturus BioCloud logo

Arcturus BioCloud

arcturus.io

Arcadia Science logo

Arcadia Science

arcadiascience.com

Alaya.bio logo

Alaya.bio

alaya.bio

LifeX logo

LifeX

lifex-labs.com

Luca Biologics logo

Luca Biologics

seedhealth.com

Antheia logo

Antheia

antheia.bio

ResVita Bio logo

ResVita Bio

resvitabio.com

Vibe Bio logo

Vibe Bio

vibebio.com

Orchid BioVentures logo

Orchid BioVentures

Aurita - Quick Facts

Who are Aurita's competitors?

Companies similar to Aurita include Aureka Biotechnologies, Aurion Biotech, Arytha Biosciences and Pearl Bio.

When was Aurita founded?

Aurita was founded in 2021.

Where is Aurita's headquarters located?

Aurita's headquarters is located in Gainesville, FL, US.

When was Aurita's last funding round?

Aurita's most recent funding round was for $1M (USD) in July 2022.

How much has Aurita raised to-date?

As of Jul 7, 2022, Aurita has raised a total of $1M (USD).

How many employees does Aurita have?

Aurita has 6 employees as of Feb 4, 2024.

Aurita - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Bioscience
  • Therapeutics
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software